Back to top
more

Alkermes (ALKS)

(Real Time Quote from BATS)

$27.12 USD

27.12
746,353

+0.53 (1.99%)

Updated Oct 10, 2024 02:16 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Alkermes (ALKS) Earnings Expected to Grow: What to Know Ahead of Q4 Release

by Zacks Equity Research

Alkermes (ALKS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Techne (TECH) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Techne (TECH) delivered earnings and revenue surprises of 3.30% and 0.84%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Epizyme (EPZM) Stock Dives on Public Offering of Common Stock

by Zacks Equity Research

Epizyme (EPZM) to issue secondary shares, which will significantly dilute its current shareholder base. Consequently, share price declines.

BridgeBio (BBIO) Begins Dosing with Gene Therapy in CAH Study

by Zacks Equity Research

BridgeBio (BBIO) doses the first patient in a phase I/II study evaluating its investigational gene therapy candidate, BBP-631, for treating classic congenital adrenal hyperplasia.

ALX Oncology's (ALXO) Evorpacept Gets Orphan Drug Tag for GC

by Zacks Equity Research

The FDA bestows an Orphan Drug status to ALX Oncology's (ALXO) lead candidate, evorpacept, for treating gastric cancer and gastroesophageal junction cancer.

Biogen (BIIB) to Sell Biosimilar JV Stake to Samsung Biologics

by Zacks Equity Research

Biogen (BIIB) is selling its equity stake in the Samsung Bioepis joint venture to partner Samsung Biologics

Moderna (MRNA) Starts Study for Omicron-Specific Booster Jab

by Zacks Equity Research

Moderna (MRNA) doses the first participant in a phase II study on its Omicron specific COVID-19 booster candidate in a mid-stage study.

Vertex (VRTX) Q4 Earnings & Sales Beat, '22 View Upbeat

by Zacks Equity Research

Vertex Pharmaceuticals' (VRTX) earnings and sales surpass estimates for the fourth quarter of 2021. The company provides its revenue guidance for 2022.

Horizon (HZNP) Begins Enrollment in Rare Lung Disease Study

by Zacks Equity Research

Horizon (HZNP) enrolls the first patient in a phase IIb study evaluating HZN-825 for the treatment of idiopathic pulmonary fibrosis.

Pfizer's (PFE), OPKO's BLA for Somatrogon Gets CRL From FDA

by Zacks Equity Research

The FDA issues a Complete Response Letter to Pfizer (PFE) and OPKO Health's biologics license application for somatrogon to treat growth hormone deficiency in pediatric patients.

Gilead (GILD) Drug Gets FDA Nod for Non-Hospitalized COVID Patients

by Zacks Equity Research

Gilead (GILD) gets FDA approval for label expansion of Veklury for the treatment of non-hospitalized patients at high risk for COVID-19 disease progression.

BioDelivery (BDSI) Stock Up on Raised Guidance for 2021

by Zacks Equity Research

BioDelivery Sciences International (BDSI) raises its financial guidance for full-year 2021. BDSI expects sales at the high end of its previous guidance.

Nuvation (NUVB) Gets FDA Clearance for Oncology Candidate

by Zacks Equity Research

Nuvation (NUVB) will be initiating a phase I/II study of NUV-868 as a monotherapy and in combination with Lynparza or Xtandi in multiple tumor types following IND clearance by the FDA.

ChemoCentryx (CCXI) Tavneos Gets EU Nod for ANCA Vasculitis

by Zacks Equity Research

Following approval in the EU, ChemoCentryx (CCXI) plans to launch Tavneos for treating ANCA-associated vasculitis in first-half 2022.

Zogenix (ZGNX) Stock Surges on Acquisition Offer From UCB

by Zacks Equity Research

Belgium-based UCB is set to acquire Zogenix (ZGNX) for a total transaction value of $1.9 billion in cash. The transaction is likely to be completed by second-quarter 2022.

Regeneron (REGN)/Sanofi's Libtayo sBLA Accepted by the FDA

by Zacks Equity Research

Regeneron (REGN) sBLA seeking label expansion of Libtayo in combination with chemotherapy as first-line treatment in advanced lung cancer accepted by the FDA.

Zacks.com featured highlights include: Alkermes, Tesla, Nucor Corp. and GoPro

by Zacks Equity Research

Alkermes, Tesla, Nucor Corp. and GoPro are highlighted in this Screen of the Week article.

bluebird (BLUE) Gene Therapies BLA Decision Delayed, Stock Down

by Zacks Equity Research

The FDA delays decisions dates on bluebird bio's (BLUE) regulatory submissions for beti-cel in thalassemia and eli-cel in cerebral adrenoleukodystrophy by three months.

Phillips (PHG) Blends 3D Mapping With Zenition, Aids Prospects

by Zacks Equity Research

Phillips (PHG) integrates AI and 3D mapping capabilities it its Mobile C-Arm System, Zenition, enhancing its diagnostic imaging portfolio.

Vaishali Doshi headshot

4 Top-Ranked Liquid Stocks to Boost Portfolio Returns in 2022

by Vaishali Doshi

Here are four top-ranked liquid stocks, Alkermes (ALKS), Tesla (TSLA), Nucor (NUE) and GoPro (GPRO), which investors can tap for healthy returns.

Bausch (BHC) Eye Care Business Files for IPO in the US & Canada

by Zacks Equity Research

Bausch (BHC) eye care business files for an initial public offering in the United States and Canada.

Vaxxinity (VAXX) Starts Dosing in Parkinson's Disease Study

by Zacks Equity Research

Vaxxinity (VAXX) starts dosing patients in part B of a phase I study on its investigational Parkinson's disease vaccine candidate.

IMV Doses First Patient in the Mid-Stage Study With Keytruda

by Zacks Equity Research

IMV (IMV) doses first patient in the phase II study evaluating lead compound, maveropepimut-S (MVP-S), in combination with Keytruda

BioCryst (BCRX) Stock Up on Q4 Orladeyo Preliminary Sales

by Zacks Equity Research

BioCryst's (BCRX) sole marketable drug, Orladeyo reports preliminary sales for the fourth quarter. The company also provides its revenue guidance for 2022.

Allogene (ALLO) Clinical Hold on CAR-T Studies Removed by FDA

by Zacks Equity Research

The FDA removes the hold on Allogene's (ALLO) clinical studies evaluating AlloCAR T therapy candidates after investigations confirmed that there is no chromosomal abnormality in its candidates.